European Commission grants conditional marketing authorization for Gilead’s Veklury (remdesivir) for the treatment of COVID-19

Gilead

3 July 2020 - Veklury is the first approved treatment option for COVID-19 in the European Union.

Gilead Sciences today announced that the European Commission has granted conditional marketing authorisation for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. The conditional marketing authorisation was granted in the interest of public health due to the COVID-19 pandemic and was based on a rolling review of supporting data that began in April 2020.

Under this authorisation, Veklury is indicated for the treatment of COVID-19 in adults and adolescents (aged 12 years and older and weighing at least 40 kg), with pneumonia requiring supplemental oxygen.

Read Gilead press release 

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine